Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed - Featured image
GLP-1 Medications

Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·January 18, 2026·2 min read

On this page

  • Tom Brady's Pivot to Business Leadership
  • Entry into GLP-1 Medications
  • Sports Team Ownership Stakes
  • Fashion and Wellness Brands
  • Broadcasting and Media Ventures
  • Other Investments and Endorsements

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.

Share

On this page

  • Tom Brady's Pivot to Business Leadership
  • Entry into GLP-1 Medications
  • Sports Team Ownership Stakes
  • Fashion and Wellness Brands
  • Broadcasting and Media Ventures
  • Other Investments and Endorsements

Tom Brady's Pivot to Business Leadership

Tom Brady, one of the NFL's greatest quarterbacks with seven Super Bowl wins and five MVP awards, has channeled his competitive drive into business. After retiring, he invests in dozens of companies across sports, wellness, and more. His net worth stands at an estimated $530 million, per Forbes.

Entry into GLP-1 Medications

Brady recently became Chief Wellness Officer at eMed Population Health, a digital health firm specializing in GLP-1 medications. These drugs, including Wegovy (semaglutide) for weight loss and Zepbound (tirzepatide) for diabetes and obesity, have surged in popularity.

Brady emphasizes eMed's mission to improve population health through scalable GLP-1 care for workforces. "These are game-changing drugs if paired with clinical guidance," he stated. For users, tools like apps that track GLP-1 doses—such as Shotlee—support adherence and monitoring.

Sports Team Ownership Stakes

Brady maintains strong ties to sports with minority ownership in Las Vegas teams. He owns stakes in the NFL's Las Vegas Raiders (5%) and WNBA's Las Vegas Aces.

  • Raiders deal finalized in 2023; amount undisclosed.
  • Aces investment followed a 2022 game, impressed by women's basketball growth, per owner Mark Davis.

He also founded the Las Vegas Night Owls pickleball team in 2022, capitalizing on America's fastest-growing sport, according to a 2025 Sports & Fitness Industry study. In 2023, Brady acquired a 3.3% stake in English soccer club Birmingham City.

"I've got a lot to learn... but I do know a few things about winning," Brady told ESPN.

Fashion and Wellness Brands

Brady's sportswear brand, Brady Brand Clothing, launched in 2022 and merged with NOBULL in 2024, making him a major shareholder. Under NOBULL is TB12, his 2013 co-founded wellness brand offering plant-based protein powders and electrolyte supplements.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

This aligns with the $1.8 trillion U.S. wellness industry, where GLP-1 medications play a key role in weight management.

Broadcasting and Media Ventures

In 2022, Brady signed a 10-year, $375 million Fox Sports deal—the largest in sportscasting history. He un-retired briefly but now analyzes games with Kevin Burkhardt, under restrictions due to Raiders ownership.

His 199 Productions develops sports content, including Emmy-winning "Man in the Arena" and Netflix's "The Greatest Roast of All Time: Tom Brady."

Other Investments and Endorsements

Brady co-founded NFT platform Autograph in 2021, which pivoted post-market crash and merged with Future in 2025. He holds a 50% stake in sports card retailer CardVault by Tom Brady.

Endorsements include Hertz for electric and used cars, with Executive VP Jeff Adams praising his MVP status in the used car market.

Source Information

Originally published by The Independent.Read the original article →

Read next

Keep exploring

More on Wegovy

Articles covering Wegovy dosing, side effects, and clinical updates.

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
Medical Insights

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less

New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.

8 min read
Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging
Medical Research

Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging

A new clinical trial suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may help slow biological processes associated with aging in adults with HIV.

8 min read
Yes, GLP-1s Make You Thinner. But Do They Make You Freer?
Health & Wellness

Yes, GLP-1s Make You Thinner. But Do They Make You Freer?

While GLP-1 drugs like Ozempic and Wegovy offer significant medical benefits, their rise raises critical questions about freedom, body image, and the cultural pressure to be thinner.

8 min read

More in GLP-1 Medications

Prof Urges Caution on Funding Wegovy Rollout
GLP-1 Medications

Prof Urges Caution on Funding Wegovy Rollout

Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.

2 min read
GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs
GLP-1 Medications

GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs

Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.

2 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
GLP-1 Medications

South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs

One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.

4 min read
Share this article
  1. Home
  2. Blog
  3. Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community